Skip to main content

Table 2 Confirmed overall response by dose levels and by prior lines of therapy

From: Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study

  250 mg 300 mg 350 mg All
All patients     
Number of evaluable patients n = 2 n = 21 n = 50 n = 73
 Complete response, n (%) 0 0 0 0
 Partial response, n (%) 0 0 10 (20.0) 10 (13.7)
 Stable diseasea, n (%) 0 12 (57.1) 22 (44.0) 34 (46.6)
 Progressive disease, n (%) 2 (100) 7 (33.3) 16 (32.0) 25 (34.2)
 Not evaluable, n (%) 0 2 (9.5) 2 (4.0) 4 (5.5)
 ORR, %(95% CI) 0 (0–84.2) 0 (0–16.1) 20.0 (10.0, 33.7) 13.7 (6.8, 23.8)
 DCR, %(95% CI) 0 (0–84.2) 57.1 (34.0–78.2) 64.0 (49.2–77.1) 60.3 (48.1–71.6)
Patients with 2 or more prior lines of systemic therapy     
Number of evaluable patients n = 0 n = 9 n = 35 n = 44
 Complete response, n (%) NA 0 0 0
 Partial response, n (%) NA 0 5 (14.3) 5 (11.4)
 Stable diseasea, n (%) NA 4 (44.4) 15 (42.9) 19 (43.2)
 Progressive disease, n (%) NA 4 (44.4) 13 (37.1) 17 (38.6)
 Not evaluable, n (%) NA 1 (11.1) 2(5.7) 3 (6.8)
 ORR, % (95% CI) NA 0 (0.0–33.6) 14.3 (4.8–30.3) 11.4 (3.8–24.6)
 DCR, % (95% CI) NA 44.4 (13.7–78.8) 57.1 (39.4–73.7) 54.5 (38.9–69.6)
  1. aStable disease ≥ 6 weeks